Onvansertib is a 3rd generation, highly selective and oral PLK1 NCD (N-terminal catalytic domain) inhibitor that exhibited promising synergic results during clinical trials as part of a combination regimen treatment of AML and metastatic colorectal cancer [6,15]. The gene discussed is PLK1; the disease is acute myeloid leukemia.